Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celon PharmaLTS:0RKX 21 Graham Number is zł20.74 as of Mar. 2026, which is 100% below its 10-year median of 3.62. GuruFocus rates LTS:0RKX with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 604 Drug Manufacturers companies, Celon Pharma ranks better than 72.19% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-08-06), the stock price of Celon Pharma is zł22.50. Celon Pharma's graham number for the quarter that ended in Mar. 2026 was zł20.74. Therefore, Celon Pharma's Price to Graham Number ratio for today is 1.08.
The historical rank and industry rank for Celon Pharma's Graham Number or its related term are showing as below:
LTS:0RKX'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.95 Med: 3.62 Max: 10.61
Current: 1
During the past 11 years, the highest Price to Graham Number ratio of Celon Pharma was 10.61. The lowest was 0.95. And the median was 3.62.
LTS:0RKX's Price-to-Graham-Number is ranked better than 72.19% of 604
companies
in the Drug Manufacturers industry
Industry Median: 1.545
vs LTS:0RKX: 1.00
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Celon Pharma's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
22.50
/
20.74
=
1.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Celon Pharma Graham Number Related Terms
Celon Pharma Graham Number Historical Data
* Premium members only.
The historical data trend for Celon Pharma's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RKX vs ZTS, UTHR, VTRS: Graham Number Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma Price-to-Graham-Number vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Celon Pharma's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma (LTS:0RKX) has a Graham Number of zł20.74 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Celon Pharma and its competitors. This is 473% above median its historical median of 3.62. Over the past decade, Celon Pharma's Graham Number has ranged from 0.95 to 10.61. According to the industry distribution chart, Celon Pharma ranks #168 out of 604 companies in the Drug Manufacturers industry, placing it in the top 27.8%.
Is Celon Pharma's Graham Number too high?
Celon Pharma's current Graham Number of zł20.74 is 473% above median its 10-year median of 3.62. Over the past 10 years, this metric has ranged from a low of 0.95 to a high of 10.61. Based on the distribution chart, Celon Pharma ranks #168 out of 604 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Celon Pharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Graham Number compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #168 out of 604 companies for Graham Number. This puts Celon Pharma in the upper half of its industry. The industry median Graham Number is 1.55. Historically, Celon Pharma's own Graham Number has ranged from 0.95 to 10.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Drug Manufacturers company?
The median Graham Number among Drug Manufacturers companies is 1.55, based on 604 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median Graham Number is 1.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current Graham Number is zł20.74, which is 473% above median its own 10-year median of 3.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current Graham Number of zł20.74. The current Graham Number is zł20.74, which is 473% above median its 10-year median of 3.62. Celon Pharma's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current Graham Number is zł20.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
21GF Score
Get the complete analysis for LTS:0RKX
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKX has been successfully added to your 
